PBLA

Panbela Therapeutics, Inc.

1.12 USD
+0.72 (+180.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Panbela Therapeutics, Inc. stock is up 180% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 11.11% of the previous 8 June’s closed higher than May. 0% of analysts rate it a buy.

About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. focuses on developing disruptive therapeutics for the treatment of patients with cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for metastatic pancreatic ductal adenocarcinoma.

  • HC Wainwright & Co.
    Thu May 16, 13:30
    hold
    downgrade